{"product_id":"marimedinc-swot-analysis","title":"MariMed SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMariMed’s SWOT highlights a strong brand presence in regulated cannabis markets and diversified product lines, balanced by regulatory complexity and competitive pressure; our full SWOT unpacks financial impacts, tactical risks, and growth levers to guide strategic decisions. Purchase the complete, editable report for investor-ready insights, actionable recommendations, and an Excel matrix to support planning and pitches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertical Integration and Supply Chain Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMariMed runs a seed-to-sale model integrating cultivation, production, and retail, which drove 2024 gross margin expansion to ~58% on cannabis product lines and helped reduce COGS per gram by ~12% versus 2022.\u003c\/p\u003e\n\u003cp\u003eControl over supply secures inventory for its 40+ proprietary dispensaries and reduces exposure to third-party wholesale price swings that cut industry EBITDA by up to 8% in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAward-Winning Brand Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpmarimed award-winning brands like betty eddies and nature heritage top category charts with claiming a share of the u.s. thc gummy market in growing revenues yoy\u003e\n\u003cptheir focus on quality and targeted benefits built strong loyalty promoter scores above for flagship skus marimed sustain premium pricing despite category commoditization.\u003e\n\u003cpthis brand equity supported a gross margin in fy2025 giving marimed pricing power and resilience crowded markets.\u003e\n\u003c\/pthis\u003e\u003c\/ptheir\u003e\u003c\/pmarimed\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Efficiency and Financial Discipline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMariMed’s disciplined growth prioritizes profitability and positive EBITDA over rapid geographic expansion, yielding adjusted EBITDA margins near 22% in FY2024—top among mid‑tier MSOs. The lean corporate structure and asset focus cut SG\u0026amp;A to roughly 12% of revenue in 2024, helping the company preserve cash and weather capital constraints better than many peers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Geographic Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMariMed focuses capital on high-barrier, favorable-regulation states—Massachusetts, Maryland, and Illinois—where 2024 combined retail and wholesale sales exceeded $120M, producing steady cash flow and higher margins than newer markets. This strategy funded expansion into five additional states in 2023–2025 while keeping operating cash per store 18% above the national median. Concentration improves ROI and limits dilution of managerial resources.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue concentration: ~65% from MA\/MD\/IL\u003c\/li\u003e\n\u003cli\u003e2023–25 expansion funded from existing cash flow\u003c\/li\u003e\n\u003cli\u003eStores in core states: higher operating cash\/store (+18%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProven Management and Development Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe MariMed leadership combines over 50 years of cumulative cannabis and corporate finance experience, shown by 12 state licenses and $210M invested in facility development through 2025, delivering multiple cultivation and processing centers that met state inspection and licensing timelines.\u003c\/p\u003e\n\u003cp\u003eThe team’s repeated success in joint ventures and state partnerships creates a technical moat—new entrants face high capital, regulatory, and operational barriers to match MariMed’s scale and compliance record.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e50+ years combined experience\u003c\/li\u003e\n\u003cli\u003e12 state licenses (2025)\u003c\/li\u003e\n\u003cli\u003e$210M invested in facilities\u003c\/li\u003e\n\u003cli\u003eProven JV and licensing track record\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMariMed: 58% gross margin, $120M+ MA\/MD\/IL sales, 22% adj. EBITDA, $210M capex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMariMed’s seed-to-sale model drove FY2024–25 gross margins ~58% and COGS\/gram down ~12% vs 2022; 65% revenue concentration from MA\/MD\/IL (2024) produced $120M+ sales and adjusted EBITDA margins ~22% in 2024. Strong brands (Betty’s Eddies 12% US THC gummy share, N.Heritage +18% YoY 2025) and $210M capex across 12 state licenses underpin pricing power and low SG\u0026amp;A (~12% of revenue).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~58%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA margin (2024)\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue from MA\/MD\/IL (2024)\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales (MA\/MD\/IL 2024)\u003c\/td\u003e\n\u003ctd\u003e$120M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex to 2025\u003c\/td\u003e\n\u003ctd\u003e$210M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of MariMed, highlighting its core strengths, operational weaknesses, market opportunities, and external threats to inform strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a tailored MariMed SWOT summary for rapid strategic alignment and investor-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Scale Relative to Tier-1 Operators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompared with tier-1 multi-state operators like Curaleaf (2024 revenue $1.7B) and Trulieve ($1.6B), MariMed’s 2024 revenue of about $110M and footprint in under 10 states is much smaller, limiting access to large institutional capital and national market share.\u003c\/p\u003e\n\u003cp\u003eSmaller scale raises per-unit compliance and corporate overhead, so despite healthy gross margins, MariMed’s net income margin lags bigger peers—2024 adjusted EBITDA margin ~12% vs. 20%+ for top MSOs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant portion of marimed revenue in from three core markets leaving consolidated results exposed to local shocks.\u003e\n\u003cpif massachusetts the largest market faced a sales tax hike or demand drop pro forma ebitda could fall by percentage points disproportionate hit to margins.\u003e\n\u003cpexpanding into additional states would reduce concentration risk but needs sizable capital: marimed spent on expansion and m in require similar or larger funding plus management bandwidth.\u003e\n\u003c\/pexpanding\u003e\u003c\/pif\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Cost of Capital and Financing Constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLike most US cannabis firms, MariMed faces limited access to traditional banks and institutional loans because cannabis remains federally illegal, forcing reliance on costlier private debt and dilutive equity; in 2024 MariMed reported weighted average interest rates near 10–12% on private borrowings versus ~4% for comparable federally legal peers. This higher cost of capital raises annual financing expenses by an estimated $6–12 million (here’s the quick math: $100–200m of capital at 6–8% premium), which depresses free cash flow and valuation multiples. MariMed has managed its balance sheet—net debt fell to $45.3 million at year-end 2024—but the financing premium still limits aggressive expansion and reduces investor returns compared with federally legal industries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Wholesale Revenue Streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDependence on third-party retail channels means MariMed, despite vertical integration, earns roughly 55% of 2024 revenue from wholesale and branded shelf placements, tying growth to dispensary owners’ stocking choices.\u003c\/p\u003e\n\u003cp\u003eIf major partners cut shelf-space or favor house brands, MariMed could face inventory build-ups; a 10–15% drop in wholesale orders would cut quarterly revenue by about $8–12m based on 2024 sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~55% of 2024 revenue from wholesale\u003c\/li\u003e\n\u003cli\u003e10–15% wholesale decline ≈ $8–12m quarterly loss\u003c\/li\u003e\n\u003cli\u003eRisk: partners prioritizing house brands causes inventory buildup\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Brand Awareness in New Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMariMed’s brands dominate in core states but enter new markets like Ohio and Missouri with low recognition; market-share studies show brands often start below 5% awareness versus incumbents at 40%+\u003c\/p\u003e\n\u003cp\u003eBuilding equity requires heavy spend and education—estimated marketing outlays of $3–8 million per state to reach meaningful awareness levels within 12–24 months\u003c\/p\u003e\n\u003cp\u003eWithout the deep marketing budgets of multi-state operators, MariMed may lag in penetration and revenue ramp-up, risking slower dispensary sales and wholesale contracts\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew-market brand awareness often \u0026lt;5% initially\u003c\/li\u003e\n\u003cli\u003eIncumbent awareness ~40%+\u003c\/li\u003e\n\u003cli\u003eEstimated marketing cost $3–8M\/state (12–24 months)\u003c\/li\u003e\n\u003cli\u003eSlower revenue ramp, higher per-customer acquisition cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMid‑tier MSO faces margin, concentration and costly capital risks vs national leaders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSmaller scale: 2024 revenue ~$110M vs Curaleaf $1.7B\/Trulieve $1.6B, limiting capital and national share; adjusted EBITDA margin ~12% vs 20%+ for top MSOs. Concentration: ~45% 2024 revenue from three markets (MA largest); a 20% demand shock in MA cuts pro forma EBITDA ~9 ppt. Costly capital: private debt rates ~10–12% in 2024, raising annual financing cost ~$6–12M. Wholesale reliance: ~55% revenue from wholesale; 10–15% drop ≈ $8–12M\/quarter.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003ePeer\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$110M\u003c\/td\u003e\n\u003ctd\u003eCuraleaf $1.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA margin\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003ctd\u003e20%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue concentration\u003c\/td\u003e\n\u003ctd\u003e~45% top 3 markets\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesale share\u003c\/td\u003e\n\u003ctd\u003e~55%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate debt rate\u003c\/td\u003e\n\u003ctd\u003e~10–12%\u003c\/td\u003e\n\u003ctd\u003e~4% (federally legal)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eMariMed SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual MariMed SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality and fully editable.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get; buy now to unlock the full, detailed version immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752424190329,"sku":"marimedinc-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/marimedinc-swot-analysis.png?v=1772240814","url":"https:\/\/growthsharematrix.com\/products\/marimedinc-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}